DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
96	クローン病	3

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03917303 (ClinicalTrials.gov)	December 23, 2019	5/4/2019	Control Crohn Safe Trial	Control Crohn Safe With Episodic Adalimumab Monotherapy as First Line Treatment Study.	Crohn Disease;Inflammatory Bowel Diseases	Drug: Adalimumab;Drug: standard step-up care	Maastricht University Medical Center	Maastricht University;ZonMw: The Netherlands Organisation for Health Research and Development	Recruiting	18 Years	70 Years	All	158	Phase 4	Netherlands
2	EUCTR2017-004588-11-NL (EUCTR)	10/09/2019	10/09/2019	Control Crohn Safe Trial: Long term outcome and tolerability of six months adalimumab as initial treatment for newly diagnosed Crohn's disease versus standard step-up treatment.	Control Crohn Safe Trial: Long term efficacy and safety of periodic treatment with adalimumab versus standard step-care for newly diagnosed Crohn's disease. - CoCroS trial	The Chronic inflammatory bowel disease Crohn's disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]		Maastricht University Medical Centre	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	146	Phase 4	Netherlands
3	NCT01752790 (ClinicalTrials.gov)	December 2012	12/12/2012	Efficacy and Safety of Top-down Therapy in Pediatric Crohn's Disease	Efficacy and Safety of Infliximab as First-line Therapy in Pediatric Crohn's Disease: a Randomized, Controlled, Open-label Trial	Pediatric Crohn's Disease	Drug: Top-down;Drug: Step-up	University of Roma La Sapienza	NULL	Withdrawn	6 Years	18 Years	Both	0	Phase 4	Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03917303
(ClinicalTrials.gov)

December 23, 2019

5/4/2019

Control Crohn Safe Trial

Control Crohn Safe With Episodic Adalimumab Monotherapy as First Line Treatment Study.

Crohn Disease;Inflammatory Bowel Diseases

Drug: Adalimumab;Drug: standard step-up care

Maastricht University Medical Center

Maastricht University;ZonMw: The Netherlands Organisation for Health Research and Development

Recruiting

18 Years

70 Years

All

158

Phase 4

Netherlands

EUCTR2017-004588-11-NL
(EUCTR)

10/09/2019

Control Crohn Safe Trial: Long term outcome and tolerability of six months adalimumab as initial treatment for newly diagnosed Crohn's disease versus standard step-up treatment.

Control Crohn Safe Trial: Long term efficacy and safety of periodic treatment with adalimumab versus standard step-care for newly diagnosed Crohn's disease. - CoCroS trial

The Chronic inflammatory bowel disease Crohn's disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]

Maastricht University Medical Centre

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

146

Phase 4

Netherlands

NCT01752790
(ClinicalTrials.gov)

December 2012

12/12/2012

Efficacy and Safety of Top-down Therapy in Pediatric Crohn's Disease

Efficacy and Safety of Infliximab as First-line Therapy in Pediatric Crohn's Disease: a Randomized, Controlled, Open-label Trial

Pediatric Crohn's Disease

Drug: Top-down;Drug: Step-up

University of Roma La Sapienza

NULL

Withdrawn

6 Years

18 Years

Both

Phase 4

Italy